Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma
| Autor: | Ryan J Paxman, Luke T Nelson, Jin Xu, Jeffery W. Kelly, Bill Webb, Evan T. Powers |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
endocrine system
biology Chemistry Protein subunit Stabiliser nutritional and metabolic diseases Limiting 030204 cardiovascular system & hematology Article Dissociation (chemistry) 03 medical and health sciences Transthyretin 0302 clinical medicine Tetramer Human plasma Internal Medicine biology.protein Biophysics Potency 030217 neurology & neurosurgery |
| Zdroj: | Amyloid |
| DOI: | 10.6084/m9.figshare.12849842.v1 |
| Popis: | Transthyretin (TTR) tetramer dissociation is rate limiting for aggregation and subunit exchange. Slowing of TTR tetramer dissociation via kinetic stabiliser binding slows cardiomyopathy progression. Quadruplicate subunit exchange comparisons of the drug candidate AG10, and the drugs tolcapone, diflunisal, and tafamidis were carried out at 1, 5, 10, 20 and 30 µM concentrations in 4 distinct pooled wild type TTR (TTRwt) human plasma samples. These experiments reveal that the concentration dependence of the efficacy of each compound at inhibiting TTR dissociation was primarily determined by the ratio between the stabiliser’s dissociation constants from TTR and albumin, which competes with TTR to bind kinetic stabilisers. The best stabilisers, tafamidis (80 mg QD), AG10 (800 mg BID), and tolcapone (3 x 100 mg over 12 h), exhibit very similar kinetic stabilisation at the plasma concentrations resulting from these doses. At a 10 µM plasma concentration, AG10 is slightly more potent as a kinetic stabiliser vs. tolcapone and tafamidis (which are similar), which are substantially more potent than diflunisal. Dissociation of TTR can be limited to 10% of its normal rate at concentrations of 5.7 µM AG10, 10.3 µM tolcapone, 12.0 µM tafamidis, and 188 µM diflunisal. The potency similarities revealed by our study suggest that differences in safety, adsorption and metabolism, pharmacokinetics, and tissue distribution become important for kinetic stabiliser clinical use decisions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|